Quebec City, Canada and Myrtle Beach, United States, May 8, 2019 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated April 4, 2019, were elected as directors of TSO3. In addition, all other proposals submitted by management were approved.Election of Directors Based on the proxies received and the votes on a show of hands, the following individuals were elected as directors of the Company until the next annual shareholders’ meeting. Accordingly, the results are set out below:
|Name||Votes for||% for||Withheld||% withheld|
|Martin J. Madden||24,219,590||93.48||1,689,792||6.52|
|Richard M. Rumble||20,395,438||78.72||5,513,944||21.28|
|Proposals||Votes for||% for||Withheld||% withheld|
|Appointment of Independent Auditors||27,794,707||87.17||4,089,764||12.83|
Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 7, 2019, will be filed on SEDAR (www.sedar.com) under the name TSO3.
Founded in 1998, TSO3‘s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company’s website at www.tso3.com.Back to Posts